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ABSTRACT 
Production and Biocompatibility of Spider Silk Proteins in Goat Milk 
by 
Richard E. Decker Jr., Doctor of Philosophy 
Utah State University, 2018 
Major Professor: Dr. Randolph V. Lewis 
Department: Biological Engineering 
Due to its biocompatibility and impressive mechanical properties, spider silk has 
great potential for a variety of commercial applications, from biomaterials to textiles. 
Unfortunately, it is difficult and impractical to obtain native spider silk in sufficient 
quantities to fully investigate these applications. In consideration of this problem, 
recombinant spider silk proteins have been produced in a variety of hosts, including 
microbes, plants, silkworms, and goats. While these recombinant proteins have potential 
for meeting the demands associated with investigating spider silk’s impressive properties 
more fully, each of the current production methods needs to be improved upon in one 
way or another. Currently, goats produce the highest consistent yields of recombinant 
proteins, but there is room for improvement in both production capacity and protein 
length. The first focus of this dissertation was to establish a goat cell line designed to 
increase the purity and quantity of recombinant proteins produced in goat milk by 
incorporating a spider silk gene that encodes for a histidine-tagged protein into the goat 
genome. Although multiple genomic integration techniques were investigated, the 
PiggyBac
TM
 Transposon Vector System was ultimately used to successfully establish a
iv 
new “spider goat” cell line. 
The second focus of this dissertation was to investigate the biocompatibility of 
materials made from the current goat-derived recombinant spider silk proteins. Prior to 
testing the biocompatibility of these proteins, a method was developed for destroying 
endotoxins in the proteins that had been introduced during milk collection and 
downstream processing. Two in vivo biocompatibility studies were conducted in rats by 
implanting two different silk materials that had been treated using the endotoxin 
destruction method established herein. In response to the low level of biocompatibility 
discovered during these studies, another in vivo study was conducted using materials 
made from goat-derived proteins that had been purified using reverse phase 
chromatography. It was determined based on results from this final study that goat-
derived spider silk proteins are not biocompatible in their current state due to impurities 




Production and Biocompatibility of Spider Silk Proteins in Goat Milk 
Richard E. Decker Jr. 
Due to its strength, flexibility, and biocompatibility, spider silk is a highly 
appealing material for applications in the medical field. Unfortunately, natural spider silk 
is difficult to obtain in large quantities because spiders are territorial and cannibalistic, 
making them impractical to farm. Synthetic spider silk proteins produced by transgenic 
hosts such as bacteria and goats have made it possible to obtain the quantities of spider 
silk needed to study it more fully and to investigate its potential uses. The spider silk 
proteins produced in our laboratory do not have an optimal purification method to 
remove all of the non-biocompatible contaminants and have not previously been tested 
for their biocompatibility. The first focus of this dissertation was to create goat cells that 
can be used to create new goats. These new goats will produce proteins that can be 
purified more efficiently and more completely. The second focus of this dissertation was 
to perform biocompatibility tests on goat-derived spider silk proteins. Prior to performing 
any biocompatibility tests, a method was established for removing endotoxins – an 
impurity that causes an immune response in the body – from the proteins. This work has 
shed light on areas for improvement in the silk protein purification process and laid 
groundwork for the production of new goat-derived proteins. These steps will help make 
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Spider silk’s biocompatibility and impressive mechanical properties make it an 
ideal material for many applications. From wound healing among the ancient Greeks to 
crosshairs in pre-World War II optical devices, spider silk has been used by mankind for 
centuries
1,2
. Orb-weaving spider silk is of particular interest because orb-weavers produce 
six different types of silk and one glue, composed of proteins ranging in size from 200-
350 kDa (Figure 1-1)
3
. Each of these silks is unique in its molecular structure, function, 
and mechanical properties. The most studied spider silk is major ampullate silk, largely 
due to its high tensile strength and toughness
3
. Major ampullate silk is made up of two 
proteins, Major Ampullate Spidroin 1 (MaSp1) and Major Ampullate Spidroin 2 
(MaSp2)
4
. Major ampullate silk is used in web construction and is also a lifeline for the 
spider. It is often referred to as dragline silk because a spider will leave, or drag, a trail of 
major ampullate silk when walking to catch itself if it falls. The extensibility and tensile 





Figure 1-1: There are six different types of spider silk: aciniform (yellow), cylindrical or 
tubulliform (brown), flagelliform (green), major ampullate (red), minor ampullate 
(purple), and pyriform or piriform (orange), as well as one protein-glue, aggregate (blue). 
As shown (via color coding), each type of silk has a different use for the spider with 
mechanical properties that are specific to their role in survival, prey capture and/or 
reproduction
5
 (Image reprinted with permission. Credit: Patricia J. Wynne). 
 
While these mechanical properties are essential for the life of the spider, they also 
make spider silk a highly promising material for use in the biomedical field
6–8
 and for a 
variety of other uses. Some of the proposed uses for spider silk include non-medical 
applications like parachute cords, tire linings, and high-performance sportswear, as well 
as medical applications such as replacement ligaments, tissue scaffolds, drug storage 
matrices, and drug delivery systems
9–11
. Although spider silk holds great promise, natural 
silk is very difficult and impractical to harvest because spiders are territorial and 
cannibalistic. Lack of silk material makes it nearly impossible to investigate most of 
silk’s potential uses, let alone create any products at a marketable scale. 
To obtain spider silk proteins in the quantities required to study silk for its many 
proposed applications, synthetic spider silk proteins are being produced in a variety of 
transgenic hosts (Figure 1-2)
7,12–16
. There are hurdles involved with creating materials 
3 
 
from recombinant silk proteins created in transgenic hosts, such as the difficulty of 
spinning fibers from the proteins and the introduction of contaminants into the materials 
during protein production and processing that can affect the biocompatibility of the 
materials. In spite of these hurdles, there are advantages to producing silk proteins using 
transgenic hosts beyond just increased quantities of protein. Another major advantage is 
that materials made from recombinant spider silk proteins can be tailored through post-
production processing of the materials or genetic alterations to the proteins themselves to 
have increased extensibility or increased strength, further increasing the potential 





Figure 1-2. Brief history of recombinant spider silk protein production: (a) Production of 
synthetic spider dragline silk protein in Pichia pastoris in 1996
13
, (b) synthetic spider 
dragline silk proteins and their production in Escherichia coli in 1997
17
, (c) production of 
spider silk protein in tobacco and potato in 2001
12
, (d) spider silk fibers spun from 
soluble recombinant silk produced in mammalian cells in 2002
18
, (e) expression of 
EGFP-spider dragline silk fusion protein in BmN cells and larvae of silkworm, which 
showed that solubility is the primary limitation for the yield of spider silk protein, in 
2007
19
, (f) construct synthetic gene encoding artificial spider dragline silk protein and its 
expression in the milk of transgenic mice in 2007
20
, (g) transgenic silkworms (B. mori) 
producing recombinant spider dragline silk in cocoons in 2009
21
, (h) engineering 
the Salmonella type III secretion system to export spider silk monomers in 
2009
22
, (i) native-sized recombinant spider silk protein produced for the first time in 
metabolically engineered E. coli resulting in a Kevlar-strength fiber in 2010
23
, 
and (j) transgenic silkworms transformed with chimeric silkworm–spider silk genes 
producing composite silk fibers with improved mechanical properties in 2012
24
. The 
organization of the important motifs in spider silk proteins, which is modified from 
Hayashi et al.
25
 and Teule et al.
14
. The colored-squares indicate the modules contained in 
each silk protein. The proteins are: MaSp1 and MaSp2, major ampullate spidroin 1 and 2 
from Nephila clavipes; ADF-1, ADF-2, and ADF-3, minor ampullate, putative 
cylindrical, and major ampullate, respectively, from Araneus diadematus
25
 (Reprinted 
from Chung et al.
7







One potential method for producing recombinant silk proteins is through cultured 
cells. Our group has shown that spider gland cells may produce silk proteins when in 
culture, but because glandular cells do not proliferate we have been unable to 
successfully establish a glandular cell line (unpublished data). Insect cells, which should 
have similar biological and chemical properties to spider cells, have also been explored 
for spider silk production. While there are a limited number of studies relating to spider 
silk production in insect cells, spider silk-like proteins have been produced in both BmN 
Bombyx mori (BmN) cells and Spodoptera frugiperda (Sf9) cells
19,26
. One of the reports 
on silk proteins produced in BmN cells related sparse results, simply stating that the 
proteins were only about 70 kDa and “probably occupied 5% of the total cell protein”
19
. 
Vollrath et al. showed that silk could be produced in Sf9 cells that had the same chemical 
properties as natural silk, but the resulting fibers were too fragile to be tested 
mechanically
26
. While this might indicate that the proteins were not truly similar to those 
produced by spiders, the fragility was more likely due to poor fiber spinning techniques 
available at the time.  
In 2002, Lazaris et al. successfully produced silk in cultured mammalian cells, 
including bovine mammary epithelial cells and baby hamster kidney (BHK) cells
18
. Like 
fibers produced from insect cell-derived proteins, the fibers produced from the protein 
created by bovine and BHK cells were also brittle. It was suggested that this could be due 
to a depletion of the aminoacyl-tRNA pool in vitro causing truncated proteins
18
, although, 
similar to silk from insect cells, the brittleness of the fibers was more likely due to a lack 
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knowledge regarding spinning synthetic spider silk fibers available at the time (and the 
lack of proteins needed to improve that knowledge) leading to poor spinning methods. 
Unfortunately, regardless of whether silk produced in insect or mammalian cells would 
be similar to those in nature with more biomimetic spinning techniques, the cost 
associated with producing proteins in a cell line is much too high to consider on a 
commercial scale for a non-therapeutic protein. 
Bacteria (E. coli) 
 Escherichia coli (E. coli) has been well studied and has a short doubling time, 
making it an attractive host for producing high quantities of silk proteins. Because of this, 
E. coli has been used to express multiple spider silk proteins
17,27
. In 2010, researchers 
claimed to have produced silk proteins in E. coli that are similar in size to native silk 
proteins
23
, but no group has been able to reproduce these results. Because protein size is 
at least partially responsible for the strength of spider silk fibers, truncated proteins are 
detrimental to the strength of the resultant materials
23,28
. One of the proposed causes of 
the truncated proteins is that spider silk proteins are highly repetitive and contain large 
amounts of glycine, alanine, and proline
3,4,29
. E. coli have a limited tRNA pool and, 
therefore, do not produce enough of these amino acids to create full-length proteins and 
still support regular cell function. Although increased work on silk production in E. coli 
is leading to the production of larger proteins at increased quantities, other transgenic 
systems, such as plants, silkworms, and goats, have been investigated to avoid or 





There have been some notable achievements in spider silk production using 
plants. In theory, plants should be able to produce larger silk proteins without the addition 
of any tRNAs. Scheller et al. were able to produce silk-like proteins in both potato and 
tobacco plants in which there was no genetic instability caused by the recombination of 
repetitive proteins, a problem seen in some other transgenic systems
12,15
. The silk proteins 
comprised up to 2% (average >0.5%) of the total soluble protein when produced in the 
endoplasmic reticulum (ER)
 12
. It is noteworthy that the silk proteins had a high resistance 
to heat, which made them easier to extract and purify by removing smaller proteins
12
. 
Proteins of up to 100 kDa were detectable in the plant tissue, which is comparable to, if 




Our group is investigating production of spider silk proteins in alfalfa. These 
studies have led to transgenic plants that produce silk proteins predominately in their 
leaves. Transgenic alfalfa would be one of the most cost-effective systems for producing 
spider silk proteins for two major reasons: 1) alfalfa is a perennial plant, meaning 
transgenic fields could be established and then grown year after year and 2) the plant 
waste could potentially be used as feed for livestock or fuel for ethanol production, thus 
boosting the economic value of the crop as a whole. In spite of the accomplishments in 
developing plants that produce spider silk proteins and their great potential, the major 
hurdle preventing the use of plants for spider silk production at a commercially viable 
scale is the protein purification process. Using metal affinity chromatography, such as a 
His-tag purification system, is problematic because it cannot be scaled to the level 
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necessary to extract silk proteins on a large scale. Metal affinity chromatography is also 
problematic for purification from plants because chlorophyll is a charged protein that is 
extracted along with histidine-tagged silk proteins. Extracted chlorophyll leads to 
contamination, damaged metal affinity media and equipment, and lower yields of silk. 
While developing a method for extracting recombinant silk from alfalfa or other plants at 
a large scale would lead to one of the most scalable and economically sustainable 
methods for producing large quantities of spider silk proteins, purification from this 
system remains a significant challenge. 
Silkworms 
Through the use of targeted genomic integration, our laboratory group has also 
recently been able to create transgenic silkworms that produce up to 15% spider silk in 
combination with their native silk. One major advantage to using silkworms to produce 
spider silk is that they are a self-contained spinning apparatus, which removes the 
complications associated with trying to spin spider silk fibers from recombinant proteins 
with biomimetic equipment that will likely never be as good as natural spinning systems. 
Although the data is unavailable due to patent filing concerns, the fibers produced by 
transgenic silkworms have mechanical properties approaching those of native spider silk 
fibers. In spite of the benefits of using silkworms to produce spider silk, there are still 
some downfalls: 1) the silkworms still produce sericin, a protein glue that is 
immunological, which must be removed via multiple treatment steps before the silk can 
be used as a biomaterial, and 2) extensive processing of the fibers is required to make it 
possible to create non-fiber materials. In both cases, the processing required can lead to a 




Following the work done by Lazaris et al. to produce spider silk in mammalian 
cells
30
, Nexia Biotechnologies, in cooperation with Dr. Randy Lewis, created transgenic 
goats that produce spider silk proteins in their milk (Nexia Biotechnologies, unpublished; 
2002)
31
. Those goats’ offspring are currently the best system for producing large amounts 
of transgenic spider silk proteins, albeit at a shorter size than native proteins (65 kDa). In 
spite of their shorter size, the large quantity of available protein has enabled 
improvements to be made in the spinning process, which has led to fibers that are 
mechanically more similar to native fibers
32
, as well as the investigation of other silk-
based materials such as thin films and hydrogels
33,34
. 
Transgenic goats are ideal animals to work with for the production of spider silk 
proteins in milk. Goats are relatively small, their waste is easy to dispose of, and they 
produce a reasonably large amount of protein-rich milk. The spider silk genes are 
heritable, so the herd size can be scaled up relatively easily through standard goat 
breeding. Although scalable purification is a concern for using goat-derived silk proteins 
for markets requiring excessive amounts of materials such as the textile industry, using 
the proteins for medical applications is economically favorable given the lower amount of 
silk that would be required and the high value of the materials compensating for more 
costly production when compared to alfalfa or E. coli
35
. Also, the FDA has previously 
approved the production of pharmaceuticals in goats’ milk
36
, so there is a standardized 
pathway for FDA approval. Goats are, therefore, currently the optimal method for 
obtaining transgenic silk for medical applications because they will allow for protein to 
10 
 
be produced at high enough quantities in a relatively short period of time and in an FDA 
approvable manner. 
Dissertation Research Aims 
Aim 1: Transgenic Goat Cell Line 
To create the “spider goats” in use today, Nexia incorporated spider silk genes 
into a modified version of the pBC1 Milk Expression Vector system (Invitrogen, no 
longer commercially available). The pBC1 plasmid uses the goat β-casein promoter to 
produce a protein of interest in a host’s milk. Not only is the pBC1 plasmid extremely 
large (22 kb) and difficult to modify due to its multiple cloning site containing a single 
restriction enzyme cut site, but it also utilizes random integration to incorporate its cargo 
into the host genome. Although many random integration systems can be used to 
effectively incorporate a gene of interest into a host, there are potential issues with 
random integration, beyond the obvious problem of not knowing ahead of time where the 
foreign gene will integrate into the host genome. It is possible that the gene of interest 
will be incorporated such that it will interrupt an existing gene, thus silencing production 
of a native protein, or that the gene of interest will be incorporated at a locus that will 
generate lower protein yields. Since the creation of the original “spider goats,” there have 
been advances in genome editing that have led to the development of techniques that are 
superior to pBC1 for incorporating a foreign gene into a host genome. The first aim of 
this dissertation was to explore some of these improved techniques of genomic editing in 
order to establish a transgenic goat cell line to be used for somatic cell nuclear transfer to 
create goats that will produce histidine-tagged proteins from a codon optimized silk gene. 
Although this work is presented in Chapter 2 – CRISPR and PiggyBac Mediated 
11 
 
Development of a Transgenic Goat Cell Line, some background on the targeted gene 
editing techniques investigated is provided below. 
TALENs 
Researchers have known of transcription activator-like effectors (TALEs) for 
decades, but the key to understanding their specificity was deciphered less than a decade 
ago
37
. TALEs are produced by Xanthomonas bacteria and are composed of variable 
regions that recognize specific DNA sequences
38–40
. Following the elucidation of their 
specificity, TALEs became a major topic of interest. Cermak et al. developed a method to 
engineer transcription activator-like effector nucleases (TALENs) by combining the 
DNA fragments coding for naturally occurring TALEs with a mutated FokI 
endonuclease
39
. These engineered TALENs can be designed to create double-stranded 
breaks (DSBs) at nearly any region of the genome of nearly any host
39–41
. In 2012, 
Carlson et al. successfully used TALENs to facilitate a gene knockout in livestock, 
proving that engineered TALENs are a viable method for creating DSBs and genetic 
manipulation in large mammals
40
. One potential drawback of using TALENs is that each 
DSB requires a pair of TALEN proteins. This increases the load placed on the cells into 
which the TALENs are transfected and can decrease the transfection efficiency, 
especially if multiple cuts are needed. In spite of this, it has been shown that when two 
TALENs are used in tandem the efficiency of gene modification was similar to that of the 
predecessor to TALENs, Zinc Finger Nucleases (ZFNs), but without the unintended 







The newest site-specific gene editing tool employed in this project is clustered 
regularly interspaced short palindromic repeats (CRISPRs). CRISPRs create CRISPR-
associated (cas) proteins, which are RNA-guided nucleases that create targeted DSBs
42
. 
The most commonly used cas is Cas9, which has been shown to function in many 









Compared to other engineered site-specific nucleases such as zinc-finger nucleases and 
TALENs, CRISPRs are quicker, easier, and less expensive to create, in that they only 
require a standardized plasmid and a 17-22 bp double-stranded oligonucleotide matching 
the target sequence. There have been concerns regarding off-target recognition and 
cleavage by the CRISPR/Cas9 method due to the smaller size of the recognition sequence 
leading to off-target recognition and non-specific cleavage
43
, but it has been shown that 
using shorter recognition sequences actually decreases the frequency of off-target 
cutting
50
. The low cost and ease of production, diverse targets and hosts, and high 
efficiency of CRISPR/Cas9 make it one of the most promising gene editing systems 
available. The impact the CRISPR/Cas9 system is having on research in biotechnology, 
agriculture, and gene therapy and other medical applications, such as providing a 
potential “cure” for HIV-1
51
, is very impressive
52
. 
Aim 2: Endotoxin Removal and Biocompatibility Studies 
 Although native spider silk is well known as a biocompatible material, synthetic 
spider silk produced in our laboratory (both goat- and bacterially-derived) has not been 
tested for its biocompatibility. To bring synthetic spider silk into the medical field, 
biocompatibility tests are essential. Results of these tests can either be used to confirm 
13 
 
biocompatibility or elucidate areas of improvement in protein purification and processing 
to establish biocompatibility. As such, the second aim of this dissertation was to perform 
biocompatibility tests on materials made of goat-derived spider silk proteins. 
 Aim 2-1: Endotoxin Removal 
One major concern when preparing to test the biocompatibility of any biomaterial 
is the presence of endotoxins. Endotoxins, also known as lipopolysaccharides (LPS), are 
small, heat stable toxins present in gram-negative bacteria that are released during growth 
and upon cell death. Endotoxins can illicit an immune response independent of the effects 
of the biomaterial itself, thus producing confounding results in biocompatibility studies
53
. 
Consequently, it is essential to ensure endotoxins are removed from or destroyed in any 
biomaterial prior to investigating its biocompatibility. The most common methods for 
endotoxin removal/destruction – dry heat (>180 °C) and caustic rinses (e.g. NaOH) – 
cannot be used on most proteins, including spider silk, as they denature and/or leave 
residual chemicals in the proteins
53
. In the case of spider silk, this is detrimental, as 
denaturation of the proteins leads to the loss of mechanical properties and negates one of 
the key reasons for using spider silk as a biomaterial. To avoid these issues, a method to 
destroy endotoxin in synthetic spider silk protein, without compromising its mechanical 
abilities, was developed and employed to prepare samples for in vivo biocompatibility 
tests. This method and its effectiveness are presented in Chapter 3 – Method for the 
Destruction of Endotoxin in Synthetic Spider Silk Proteins. 
 Aim 2-2: In vivo Biocompatibility Tests 
 Although in vitro tests were performed on our synthetic spider silk using Chinese 
hamster ovary cells and BHK cells (unpublished data), these tests did not provide much 
14 
 
useful information regarding the silk’s biocompatibility beyond demonstrating that the 
silk does not appear to affect cell viability or have any cytological effects on the cells. To 
obtain impactful data on the biocompatibility of goat-derived spider silk, in vivo tests 
were conducted in rats using spider silk films and hydrogels that had been treated with 
our newly developed method for endotoxin destruction (Chapter 3). The details and 
results of those in vivo studies are presented in Chapter 4 – Investigation of the In Vivo 
Biocompatibility of Goat-derived Spider Silk Protein. Chapter 4 also includes 
information regarding an effort to redesign the processing and purification pathway of the 
goat-derived silk proteins in an attempt to reduce the inflammatory response seen in our 
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CRISPR AND PIGGYBAC MEDIATED DEVELOPMENT OF A TRANSGENIC  
GOAT CELL LINE 
Chapter Preface 
This chapter presents work completed and problems encountered relating to 
incorporating a spider silk protein gene into the goat and hamster genomes. Four methods 
of incorporating the spider silk gene were employed: transcription activator-like effector 
nucleases (TALENs), pBC1, clustered regularly interspaced palindromic repeats 
(CRISPRs) and CRISPR associated protein 9 (Cas9), and PiggyBac. TALENs and 
CRISPR/Cas9 were both used to produce targeted double-stranded breaks in the genome 
and induce homology directed recombination (HDR). PiggyBac and pBC1 are both 
random integration plasmid systems into which the spider silk gene was incorporated. 
The pBC1 Milk Expression Vector (Invitrogen, K270-01), which utilizes the goat β-
casein promoter to facilitate protein production in milk, is no longer commercially 
available, but it was the original expression system used to create transgenic “spider 
goats,” which is why its use was attempted early on in the project. 
TALENs and pBC1 were used in the early stages of the project (first year, 2012-
2013), but there were many difficulties associated with both systems, especially in 
regards to determining whether either system had worked successfully. Although 
repeated attempts were made to use the TALEN system to cleave the goat genome, no 
success was observed. It is possible that this was due to the nature of the cleavage being 
attempted – two cuts to remove a large portion of the genome (~11kb), requiring four 
TALEN plasmids (two per cut). It is also possible that cleavage (TALENs) and 
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incorporation (pBC1) was not detected due to low transfection, expression, and 
incorporation efficiencies. This, combined with a lack of selection markers to promote 
proliferation of successfully transfected/edited cells, would have made it nearly 
impossible to detect positive results.  
Because the CRISPR/Cas9 system was developed in 2013, soon after the start of 
the project, the TALEN and pBC1 systems were abandoned in favor of this easier, less 
expensive, higher efficiency method. In light of this, the TALEN and pBC1 work will not 
be included in the following chapter, as it does not add any significant value to the work 
attempted and completed. Regardless, the researchers would like to acknowledge that the 
plasmid kit used for generation of TALENs in this project was a gift from Daniel Voytas 








 Genetic manipulation of organisms by humans has been conducted for millennia, 
from farmers selectively growing crops to breeders selectively breeding for particular 
traits in animals. Although genetic work has been conducted in a laboratory setting for 
nearly a century, much of this work has been conducted using random integration 
methods – a gene of interest is “forced” into the genome at a random or semi-random 
location. Using these random integration methods, the gene of interest is usually 
incorporated at multiple loci within the genome that can be difficult, if not impossible, to 
determine. Fortunately, genetic manipulation has become significantly more 
“programmable” and consistent over the last two decades thanks to the discovery of 
programmable nucleases such as zinc finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and clustered regularly interspaced repeats (CRISPRs) 
and CRISPR associated proteins (Cas), with Cas9 being the most widely used Cas
2,3
. 
With the advent of these technologies, it has become possible to quickly, easily, and 
precisely make modifications to the genome of many different organisms. The 
applications for targeted genomic engineering range from studying diseases, particularly 
genetic diseases, to the amplification or addition of specific traits in food crops such as 
rice, to altering the genome of a mammal
4–8
.  
 One interesting example of genetic manipulation is the production of spider silk in 
transgenic goats’ milk
9
. Spider silk, particularly major ampullate or dragline silk, has 
gained a lot of interest as a potential biomaterial due to its strength and 
biocompatibility
10–12
. Due to complications with farming spiders efficiently at a large 
scale, synthetic spider silk has been investigated as a substitute for natural spider silk. 
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, the most consistently high yields of larger 
spider silk proteins are currently produced in transgenic goats. Unfortunately, the silk-
coding genes have been randomly integrated into the goat genome using an outdated 
system (pBC1) without provision for affinity chromatography. Because of this, it is 
believed that the goats may not produce silk as efficiently as possible. It is also 
speculated that the current protein purification process not only leads to a loss of protein, 
but also increases the opportunity for contamination with endotoxin and other 
environmental contaminants. To address these issues, we sought to integrate a spider silk 
gene with a histidine tag at a targeted locus in the goat genome.  
The main focus of this study was to replace one of the native milk protein coding 
genes in the goat genome, specifically the αS2-casein gene, with a gene encoding one of 
the two proteins that make up dragline silk, specifically major ampullate spidroin 1 
(MaSp1)
18
. We theorized that incorporating the MaSp1 gene in the genome such that it 
would be controlled using the native protein production, excretion, and packaging 
systems of the goat would improve the quality and increase the quantity of the spider silk 
protein being produced by the goat. To attempt this, the CRISPR/Cas9 system was 
employed to induce multiple double-stranded breaks (DSB) in the regions of the genome 
surrounding the αS2-casein locus in order to incorporate the MaSp1 gene into the genome 
via homology directed recombination (HDR). 
Although fully removing and replacing an existing gene via targeted DSB 
production and subsequent HDR was the ideal situation in this project, there are many 
complexities associated with the work that make the process extremely difficult to 
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complete. Therefore, it was concluded that, even if full gene replacement was not 
possible, randomly incorporating a MaSp1 gene with a histidine tag would still have an 
important impact on improving the overall amount and purity level of silk protein 
obtained. In light of this, the PiggyBac
TM
 Transposon Vector System, a semi-random 
integration system, was used as a contingency plan for integrating silk genes with a 
histidine tag. 
 Due to some issues early on with knocking the silk into the goat genome, we also 
attempted to knock the same silk construct into the Syrian hamster (Mesocricetus 
auratus) genome as a pilot study to determine whether our method (using CRISPR/Cas9 
and HDR to incorporate a large gene) would be feasible before continuing the work in the 
goat genome. Hamsters were chosen for their shorter gestational period and available 
secondary cell line – baby hamster kidney (BHK) cells. The BHK cell line is very hardy 
and easy to work with. Also, CRISPR gene editing in hamsters has been successfully 
accomplished by others previously
6,7,19
. 
Herein we present the hurdles, failures, and successes associated with integrating 
a histidine-tagged spider silk gene into the goat genome. 
Materials and Methods 
CRISPR/Cas9 
 CRISPR/Cas9 constructs (referred to herein as CRISPRs) were created by 
incorporating CRISPR guide RNA sequences (gRNAs) into the pX330-U6-
Chimeric_BB-CBh-hSpCas9 plasmid backbone, referred to herein simply as pX330. 
pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid # 
42230)
20
. Guide RNAs were selected using the CRISPR Design tool at crispr.mit.edu 
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with NGG as the protospacer adjacent motif (PAM) sequence. Guides of 17-20 bp were 
prioritized. Potential off-target loci were determined by running the gRNAs in BLAST 
against the goat or hamster genome to find sites that matched the seed sequence (first ~10 
bp) and included the PAM sequence. Hamster off-target scores were also assessed via the 
Benchling CRISPR design wizard tool. Based on these criteria, no off-target sites were 
predicted.  
 The efficiency of each CRISPR was determined using the GeneArt Genomic 
Cleavage Detection Kit (Life Technologies A24372). CRISPRs determined to have the 
highest efficiency were also tested together in pairs to determine whether their efficiency 
would persist when co-transfected. Based on the results of these efficiency tests, final 
gRNAs were selected – the highest efficiency gRNA sequences are shown in Table 2-1. 
 
Table 2-1. Highest efficiency gRNAs incorporated into the pX330 plasmid to create 
CRISPR constructs. Duplexes of these sequences were created by IDTDNA with “sticky 
end” overhangs (not shown) to facilitate incorporation into pX330. 
Target 
Genome 
Name Sequence (5’ – 3’) Notes 
Goat CRISPR 2 TCTTTGATTATAGGTTTC  
 CRISPR 3 GAAACCTATAATCAAAGA  
 CRISPR 8 GTCTTAGGTTGAGTCCA For distal end of gene 
Hamster CRISPR U2 GGCTTGAGTATCTCATTCTGG  
 CRISPR U5 AACTATTTAGCATTAACACG For NHEJ work 





 Transposon Vector System (System Biosiences, PB513B-1) 
(referred to herein as PiggyBac), a semi-random integration method, was also used to 
incorporate a spider silk gene into the goat genome. In order to facilitate silk production 
in milk, the goat β-casein promoter was incorporated into PiggyBac along with the spider 
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silk gene. A Neomycin resistance cassette (neo cassette) was also incorporated into 
PiggyBac to allow for cell selection. Separate regulatory elements (promoter and stop 
codon) were incorporated for the neo cassette. A plasmid map of the final PiggyBac 
construct is shown in Figure 2-1. 
 
Figure 2-1. Plasmid map of final PiggyBac construct with incorporated promoter, silk 
coding sequence (MaSp1 (16x)), histidine tag, and neomycin resistance gene. 
 
Silk Sequences and Homology Arms 
 MaSp1 and MaSp2 silk sequences used in this project were 16x repeats of 
sequences created by LifeTechnologies specifically for our research group. Each 16x 
repeat is 2046 bp long and encodes for an approximately 74 kDa protein. For pBC1 and 
PiggyBac studies, silk sequences were cloned into a custom designed insert containing a 
Kozak Consensus Sequence and milk secretion signaling sequence. For targeted 
integration studies, silk sequences were cloned between two homology arms 
(approximately 500 bp each) matching the flanking regions of the TALEN or CRISPR 
target sites in either the goat αS2-casein or hamster β-casein genes to encourage silk 
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integration via homology directed repair (HDR). Primers for the production of these 
homology arms are shown in Table 2-2. 
 
Table 2-2. Primers used for PCR and homology arm production. 




Goat Silk Up F GGGAGGCAGGCTTCATGTT 
Goat MaSp1 Up R CCTGCACCACCGGTCATATG 
Goat UF3 GCCCAAATGAGCCTCCAC 
Goat UR4 TCTGTGACTCTCCTGAACTTT 
 Ham Silk Int Up 2 F GGTAGCCCATGGAGGAGTCTTTAGAC 
 Hamster BUF1 AGGAGGCAGAGTATAGTTTGAC 
 Hamster BUR1 GGATATGCTGAGTGATTCCTTTTG 
 MaSp1 Ham Check CCACCGGTCATATGGCCG 
 MaSp2 Ham Check GGACCGGTCATATGGCCG 
 MaSp1 F1 TAGCCAGGGTGCCGGTCG 





Ham Arms UF CAGCATACATCCAAAAGGCCAAAA 
Ham Arms UR AATCCGGATGCAAAAGCAAGTGCCAC 
Ham Arms DF AATCCGGAAAGGTCTAAGAGGATTTCCAGG 
Ham Arms DR GAAGTCACGACCCACATGTTG 
 Ham HA2F AATCCGGATGTCCAAAGGGAAATTCAGTGG 





New Goat HA DF AATCCGGATGAAGATGGACAAAAATACCACTTC 
New Goat HA DR TTGTTGCTCTTTAGTCTCTCAGTCGTG 
New Goat HA UF GCATTTCTGATGATTCTCCACAAG 
New Goat HA UR TTTCCGGATGCAAGGGCAACGGCC 
 
Cell Culture 
 For all goat studies, goat fetal fibroblast (gFF) cells, provided by Dr. Irina 
Polejaeva’s research group at Utah State University, were used. For all hamster studies, 
BHK cells, provided by Zhongde Wang’s research group at Utah State University, were 
used. All cells were cultured in high glucose Dulbecco’s Modified Eagle Media (DMEM) 
(VWR VWRL0101-0500) with 10% (v/v) Fetal Bovine Serum (FBS) (GE Healthcare 
SH30071.03) and 1% (v/v) penicillin/streptomycin (Life Technologies 15140-122); non-
essential amino acids (NEAA) were also added to a final concentration of 5% (v/v) for 
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BHK cells. Cells were grown with 5% CO2 at 37 °C, with regular passaging. 
Cryopreserved cells were stored in complete media with an additional 10% FBS and 10% 
DMSO. 
Transfection and Cell Selection 
 All transfections were conducted using the 4D-Nucleofector
TM
 X Unit (Lonza 
AAF-1002X). For gFF cells, Lonza’s Amaxa
TM
 P3 Primary Cell 4D-Nucleofector
TM
 X 
Kit was used (Lonza V4XP-3024). For BHK cells, Lonza’s Amaxa
TM
 SE Cell Line 4D-
Nucleofector
TM
 X Kit L was used (Lonza V4XC-1024). Based on preliminary cell 
viability and transfection efficiency experiments (data not shown) the EO-114 program 
was used for gFF cells. The CA-137 program was used for BHK cells as recommended 
on Lonza’s website. Due to variance in cell viability levels post-transfection, the number 





gFF cells were used and 0.3x10
6
 BHK cells were used.  
For PiggyBac experiments, a PiggyBac vector expressing green fluorescent 
protein (GFP) was used as both a positive transfection control and a negative Neomycin 
selection control. A PiggyBac vector containing a neo cassette was transfected as a 
positive antibiotic selection control. Non-transfected cells were plated as a negative 
antibiotic selection control. Cell selection was achieved by adding 900 µg/mL G418 
Sulfate (VWR 97063-060) to the DMEM media starting at 48 hours post-transfection. 
Transfected cells were not harvested until complete cell death in negative control wells 
(typically ≥12 days). 
Some cells were diluted and plated in a 96-well plate at ~200 cells/well to 
establish single cell colonies. Remaining cells were plated in 6-well plates. Cells grown 
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in 96-well plates with the highest probability of being single cell colonies (chosen based 
on visual inspection) were transferred to 12-well plates when they reached 50% 
confluence. Cells grown in 12-well plates were then harvested for analysis and 
cryopreservation at 50% confluence. Cells grown in 6-well plates were harvested at 
>90% confluence for analysis and cryopreservation. 
Genomic DNA Extraction and PCR 
Following transfection and cell selection, genomic DNA (gDNA) was extracted 
from cells using the Qiagen QIAamp DNA Mini Kit (Qiagen 51304). Genomic DNA was 
then evaluated via PCR using custom primers to detect for genetic changes in the form of 
base pair insertions or deletions (indels) in the case of CRISPR evaluation studies or to 
check for silk integration. Primers used in these PCRs are listed in Table 2-2. PCR bands 
were extracted using Promega’s Wizard SV Gel and PCR Clean-Up System (Promega 
A9281). Samples were then sequenced via the Sanger method. 
Results and Discussion 
CRISPRs in Goats, Part I 
 Initially, there were concerns that the CRISPR/Cas9 system would not work as we 
were hoping, specifically to knockout and replace the αS2-casein gene. Because many of 
the common cleavage detection kits in use now were not available during the initial 
stages of the project, the efficiency of the CRISPRs being used had not been properly 
evaluated. In spite of this, we attempted to incorporate spider silk anyway and then 
focused on looking for silk incorporation to determine whether the CRISPR and HDR 
method had worked. Unfortunately, this was not an ideal process to determine whether 
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the CRISPRs were working effectively, as it was dependent on the success of the silk 
integration. After numerous attempts to incorporate silk using a dual cutting 
CRISPR/Cas9 strategy, it was determined that it would be beneficial to conduct a proof 
of concept study in a hamster model.  
CRISPRs in Hamsters 
 The CRISPR gRNAs used in hamster work were designed around the β-casein 
gene – the only known milk protein gene produced in hamster milk – and the CRISPRs 
with the highest cutting efficiency were selected. Genomic DNA of BHK cells 
transfected with CRISPRs targeting both ends of the β-casein gene was extracted 72 
hours post-transfection. Analysis of the gDNA indicated that both CRISPRs were cutting 
when co-transfected. BHK cells were then transfected with CRISPRs and the plasmid 
containing homology arms and the spider silk gene. PCR analysis performed on the 
gDNA of these cells (also extracted 72 hours post-transfection) did not indicate 
successful incorporation of the spider silk gene. Because multiple iterations of the same 
experiment yielded the same results, CRISPRs and homology arms targeting/matching 
the flanking regions of the start codon and secretion signal of the β-casein gene were 
selected. Although HDR was the preferential repair mechanism for this study, the new 
“upstream” CRISPR was selected such that it would create a double-stranded break 
(DSB) in the middle of the homologous region of the genome and donor DNA, thus 
facilitating Obligate Ligation-Gated Recombination (ObLiGaRe), a method for site-
specific gene insertions described by Maresca et al.
21
. Briefly, ObLiGaRe takes 
advantage of the NHEJ repair mechanism to ligate exogenous DNA into a specific locus 
in the genome by using a target specific genomic editing tool that recognizes both the 
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donor DNA and the target site in the genome
21
. The new CRISPRs designed to induce 
ObLiGaRe were evaluated for efficiency, and then co-transfected with the homology 
arm/silk construct. Genomic DNA was extracted after 72 hours and subjected to PCR 
analysis and subsequent sequencing. Both analyses showed that the CRISPRs had 
successfully produced indels, with the strongest sequence detected via sequencing 
showing spider silk gene integration (Figures 2-2 and 2-3). It is of note that the precise 
integration point of the 3’ end of the gene could not be determined via PCR regardless of 
the primer pairs used. Due to the impracticality of producing “spider hamsters,” these 
results were deemed sufficient to validate the feasibility of creating new spider goats 
using the CRISPR/Cas9 system (and to establish the skills of this researcher). 
Consequently, neither a transgenic cell line nor transgenic hamster pups were created. 
 
 
Figure 2-2. Gel electrophoresis analysis of PCR run on BHK gDNA. Primer pairs: (S1 or 
S2) Ham Silk Int Up 2F + MaSp1 (or MaSp2) Ham Check; (B) BUF1 + BUR1. Gel 1 – 
lane 2: BHK gDNA negative control (S1); lanes 3-6: cells transfected with MaSp1 (S1); 
lanes 7-8: MaSp1 plasmids (not gDNA) (S1); lane 9-14: DNA negative controls (same as 
3-8, but no primers); lane 15: primer negative control (S1, no DNA). Gel 2 – lane 2: BHK 
gDNA negative control (S2); lanes 3-4: cells transfected with MaSp2 (S2); lane 5: 
MaSp2 plasmid (not gDNA) (S1); lane 6-8: DNA negative controls (same as 3-5, but no 
primers); lane 9: PCR positive control, BHK gDNA (B); lane 10: negative controls (no 
DNA or primers); lane 11: negative primer control (S2). White arrows indicate bands 
representing silk integration. Ladder: Thermo Scientific GeneRuler
TM






Figure 2-3. (Top) Electropherogram produced by sequencing a PCR run on gDNA 
extracted from post-transfected BHK cells. Blue box and arrow indicate CRISPR/Cas9 
target and cut site, respectively. Red box highlights spider silk sequence. (Bottom) 
BLAST® Alignment of expected sequence (Query) and strongest signal from sequencing 
(Sbjct). 
 
CRISPRs in Goats, Part II 
 Following the success with BHK cells, CRISPR/Cas9 work was continued on gFF 
cells. The CRISPRs used previously were re-evaluated and changed as needed to improve 
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targeting efficiency in the goat genome. Similar to the hamster project, new CRISPRs 
and homology arms were also created for the flanking regions of the start codon and 
secretion signal of the αs2-casein gene, as opposed to the entire gene. Although the 
CRISPR/Cas9 constructs consistently showed reasonable cutting efficiencies, spider silk 
could never be detected as having been incorporated into the genome. It is speculated that 
the silk could have been incorporated with the aid of selection pressure, but this avenue 
was not explored during the course of this project when using the CRISPR/Cas9 and 
HDR method. Another possibility for the lack of success in editing the goat genome is the 
recently discovered phenomenon in which the CRISPR/Cas9 complex did not detach 
from the site where it created a DSB, preventing cellular repair mechanisms from 
working properly
22
. It is also worth noting that the ObLiGaRe technique used to 
incorporate silk into the hamster genome was not investigated in goats due to concerns 
with the gRNAs targeting the αs2-casein promoter region of the genome and the 
homology arms leading to indel creation in the promoter and upsetting the potential for 
protein production. 
PiggyBac 
 The silk-containing PiggyBac vector, having been modified with a neo cassette 
and the goat β-casein promoter (Figure 2-1), was transfected into gFF cells. Following 
transfection (72 hours), GFP could be seen in >90% of the control cells under 
fluorescence microscopy. Genomic DNA was extracted from Neomycin selected cells 
14-17 days post-transfection (depending on transfection batch and complete cell death in 
negative control wells) and analyzed via PCR for silk integration. As shown in Figure 2-
4, all gDNA batches showed positive results for silk integration. These results, which 
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were confirmed via Sanger sequencing (Figure 2-5), indicated that both mixed population 
and single cell derived (or nearly single cell derived) cell lines containing the gene coding 
for the MaSp1 spider silk protein have been established. 
 
 
Figure 2-4. Gel electrophoresis analysis of PCR run on gDNA extracted from gFF cells. 
Lanes 1-8 and 10-15: PCR on cells transfected with Piggy+MaSp1; lanes 16 and 17: PCR 
on cells transfected with empty PiggyBac (negative integration control); lanes 19 and 20: 
PCR on wild type gFF cells (positive PCR control, secondary negative integration 
control); lanes 21 and 22: integration positive control; lanes 23 and 24: negative PCR 
controls (no gDNA). PCR reactions in lanes 1, 3, 5, 7, 10, 12, 14, 16, 19, 21, and 23 were 
all run with primer pair MaSp1 F1 and MaSp1 R3; all other PCR lanes were run with the 
UF2 and UR3 primer pair. White arrows indicate bands representing MaSp1 integration. 
Ladder: Thermo Scientific GeneRuler
TM






Figure 2-5. BLAST® alignment comparison of expected sequence (Query) and sequencing 
results (Sbjct) for MaSp1 incorporation into the goat genome via PiggyBac. 
 
Future Work 
The most immediate future work will be to use the transgenic gFF cells for 
somatic cell nuclear transfer during the goat breeding season. Any kids produced from 
these cells can be tested for transgenesis. Kids testing positive can then be milked and 
silk protein can be extracted from the milk using affinity chromatography. The protein 
can then be tested and compared to current goat-derived silk proteins. 
Because it is assumed that the biggest problem with introducing spider silk into 
the goat genome using the CRISPR/Cas9 system is the ability to select for positively 
transfected cells, we believe that it might still be possible to use the CRISPR/Cas9 system 
along with HDR or NHEJ to incorporate a spider silk gene into the goat genome at a 
targeted location, but further modifications to the protein coding sequence would be 
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necessary, i.e. incorporation of a selection marker. One possibility would be to include a 
strong GFP marker with the silk protein gene, as this could allow for identification of 
successful genomic integration as well as fluorescence activated cell sorting (FACS) to 
obtain only transgenic cells. Initially, FACS was attempted on gFF cells, as the pX330 
backbone vector used in these experiments contains a GFP marker, but the fluorescence 
was not strong enough. Also, the presence of GFP in this case would not have indicated 
successful genomic integration, merely successful transfection, so FACS would not have 
been effective. By incorporating a stronger GFP coding cassette with the silk, the 
possibility of successful FACS would increase significantly, which would facilitate the 
establishment of a cell line with targeted silk integration. 
Another possible selection method could be the incorporation of an antibiotic-
resistance cassette into the silk/homology arm construct. It would be necessary to ensure 
that the antibiotic-resistance cassette was controlled with its own regulatory elements, 
similar to how the PiggyBac work was done, so the resistance gene would not be 
produced as part of the silk. Otherwise, the spider silk would include an antibiotic-
resistance gene, which could cause significant problems when considering medical 
applications of the spider silk. The antibiotic-selection gene could also interfere with how 
the silk performed mechanically if it were to be produced with the silk. In spite of these 
concerns, with proper precautions antibiotic selection is a feasible approach to obtaining 
gFF cells with integrated spider silk. 
One concern with this project regardless of the integration technique is the size of 
the resultant silk proteins. The mechanical properties of spider silk are dependent on the 





length silk proteins range from 200 to 350 kDa
12,25
, while the silk proteins produced as a 
result of this project will only be ~74 kDa. Although these proteins are not as long as we 
would like, they are comparable to the goat-derived proteins currently in use. Because of 
this, they can provide sufficient data for comparison between the current goat production 
system and the modified system established through this work. If the results of these 
comparisons are in favor of the new spider goats’ proteins, larger silk-coding genes can 
be incorporated using the same methodology. 
 
Conclusion 
Although there is still work to be done, it is possible to create transgenic goat fetal 
fibroblasts with genes coding for histidine-tagged MaSp1 spider silk protein using the 
PiggyBac
TM
 Transposon Vector System. These gFF cells will make it possible to create 
new and improved “spider goats” that will make proteins that are significantly easier to 
purify. This is an important step forward in the production of spider silk proteins for 
medical applications in that it may allow for the collection of larger volumes of protein at 
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 Although synthetic spider silk has impressive potential as a biomaterial, 
endotoxin contamination of the spider silk proteins is a concern, regardless of the 
production method. The purpose of this research was to establish a standardized method 
to either remove or destroy the endotoxins present in synthetic spider silk proteins, such 
that the endotoxin level was consistently equal to or less than 0.25 EU/mL, the FDA limit 
for similar implant materials. Although dry heat is generally the preferred method for 
endotoxin destruction, heating the silk proteins to the necessary temperatures led to 
compromised mechanical properties in the resultant materials. In light of this, other 
endotoxin destruction methods were investigated, including caustic rinses and 
autoclaving. It was found that autoclaving synthetic spider silk protein dopes three times 
in a row consistently decreased the endotoxin level 10-20 fold, achieving levels at or 
below the desired level of 0.25 EU/mL. Products made from triple autoclaved silk dopes 
maintained mechanical properties comparable to products from untreated dopes while 
still maintaining low endotoxin levels. Triple autoclaving is an effective and scalable 
method for preparing synthetic spider silk proteins with endotoxin levels sufficiently low 
for use as biomaterials without compromising the mechanical properties of the materials. 
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 The biocompatibility and mechanical properties of spider dragline silk set it apart 
from most synthetic and natural materials as an ideal biomaterial. Dragline silk is made 
up of two proteins, MaSp1 and MaSp2
1,2
, whose structures make the resultant fibers 
strong, extensible, and flexible.
3
 With synthetic spider silk proteins, these properties can 
be harnessed into a variety of materials in addition to fibers, such as films, coatings, gels, 
and adhesives
4,5
. Synthetic spider silk materials (including fibers) can also be tailored to 
have increased strength and/or flexibility through mixing different ratios of the dragline 
proteins. Due to its versatility, synthetic spider silk has great potential for a variety of 
biomedical applications. 
 Although native spider silk is generally accepted as biocompatible
6,7
, it is difficult 
to obtain in large quantities because spiders can only produce a limited amount of silk in 
a day and cannot be farmed efficiently due to their territorial and cannibalistic nature. In 














While each of these expression systems has advantages and disadvantages for producing 
spider silk proteins, all are subject to contamination with environmental pyrogens, 
especially endotoxins, during production and processing. 
 Pyrogens are substances that produce a fever that can quickly become 
dangerously high. Endotoxins, one of the most prevalent pyrogens, are surface 
lipopolysaccharides (LPS) released from gram-negative bacteria that are heat stable to 
high temperatures
17
. As with all pyrogens, if endotoxins are present at high enough 
levels, they will induce a fever
18




removal or destruction is required for any implantable biomaterial
19,20
. Although 
endotoxins are produced by gram-negative bacteria, they can be found in most 
environments, particularly on a goat farm and in a laboratory environment
21
. 
 The most common method for pyrogen destruction (depyrogenation) of materials 
such as packaging and medical devices is dry heat. Materials to be depyrogenated are 
treated at 250 °C for ≥30 min
17,22
. The temperature can be adjusted, but it cannot be lower 
than 180 °C, and at that temperature the samples must be treated for ≥3 hours
22
. 
Unfortunately, most proteins and other polymers cannot withstand these high 
temperatures. Although triple autoclaving has been proposed as a potential method for 
removing endotoxin, the effectiveness of this and other alternative methods of 
depyrogenation, including caustic rinses, is often debated
17
. 
 Common methods for removing endotoxin from solutions, such as size-exclusion 
or ion-exchange chromatography, are effective for medical injectables and microbial-
produced bioproducts such as small (<100 kDa), soluble proteins. Although spider silk 
can be solubilized under specific conditions, it is likely to solidify as the conditions 
change during the endotoxin removal processes. Ion-exchange chromatography often 
leads to an increase in salt concentrations, which are detrimental to the formation of 
spider silk materials
23
, and would require additional washing steps for the silk proteins. 
Arguably the most significant problem with these methods of endotoxin removal is that 
they are most effective on smaller soluble proteins. The mechanical properties of spider 
silk materials are highly dependent on the size of the protein – larger (>100 kDa) is 
better
15,24,25
. Due to these issues, common methods for removing endotoxins cannot be 




 In light of this, a method to destroy or remove endotoxins from synthetic spider 
silk (or the materials produced from them) is needed to produce biocompatible and 
implantable materials. To our knowledge, there is no such method that has been reported 
in literature. To remedy this, we sought to determine the best method to either remove or 
destroy endotoxins present in synthetic spider silk proteins and synthetic spider silk 
protein-based materials while maintaining the valuable mechanical properties of the 
spider silk. 
 
Results and Discussion 
 As can be seen in Table 3-1, it is possible to decrease the endotoxin levels of 
synthetic spider silk protein by autoclaving three times. Dry heating also decreased the 
endotoxin level (data not shown), but even at the lowest acceptable treatment temperature 
of 180 °C the recombinant spider silk’s mechanical properties were compromised. 
Protein treated with dry heat made very poor films that could not be tested because they 
broke when handled. Similarly, dry heated fibers also became very brittle. This decrease 
in mechanical properties is likely due to the extreme dehydration and resultant 
degradation of the spider silk that occurs at high temperatures and/or pressures
23
. The dry 
heated protein also had significant discoloration (brownish-yellow or black), indicating 
that it had been charred. Due to the detrimental effects of dry heating on the mechanical 
properties of the samples, the dry heat treatment method was discarded. In contrast, the 
autoclaved protein samples maintained their color and the resultant films had mechanical 
properties similar to films made from untreated proteins (Table 3-2). It is also of interest 
that films maintained decreased endotoxin levels when they were made on endotoxin-free 




(Table A1-1, sample 15). This further confirms that autoclaving destroys the endotoxin in 
the silk proteins. 
Table 3-1. Combined average endotoxin levels of all goat-derived spider silk proteins 
and films before and after treatments. Individual sample group averages are shown in 
Table A1-1. The R
2
 of the endotoxin analysis kit standard curve was ≥0.989 for all 
experiments. Silk samples below 0.25 EU/mL are in bold. Standard deviations were 
calculated using STDEV.P in Microsoft Excel. 
Sample Type Treatment Results (EU/mL) n 
Protein Powder None 5.92 ± 0.07 2 
Film NaOH rinse + H20 rinse 2.08 ± 0.11 2 
Film NaOH rinse + H20 rinse 4.05 ± 0.42 2 
Protein Powder Doping 3.20 ± 1.71 16 
Protein Powder Doping + Autoclaving x3 0.17 ± 0.09 14 
Films Doping + Film 0.81 ± 0.36 4 
Films Doping + Autoclaving 3x + Film 0.18 ± 0.07 11 
 
 Only protein powder, dopes (protein solubilized in water using microwave 
irradiation to generate high heat and pressure; for details see Methods), and fibers were 
treated via autoclaving because films deformed (melted) when autoclaved and could not 
be tested. All film samples presented here were made from autoclaved dopes.  
 Although triple autoclaving did not cause fibers to become as brittle as dry heated 
fibers, which broke when handled, the autoclaved fibers still had a significant drop in 
mechanical properties. It was possible to handle most of the autoclaved fibers to prepare 
them for mechanical testing, but the samples broke before any meaningful data could be 
gathered during testing. Some samples were autoclaved immersed in water to test 
whether dehydration was the sole cause of the increased fragility, but the result was the 
same, indicating that the issue could be due to the combination of high temperature and 




 Because early tests indicated that it would be necessary to eliminate endotoxins in 
synthetic spider silk fibers (data not shown), dry heat and autoclaving treatments were 
investigated. While it was found that autoclaving did decrease the endotoxin level in most 
fiber samples, the results were not as consistent as those of dopes and film samples. 
Table 3-2. Data from tensile tests on films made from triple autoclaved and untreated 
synthetic spider silk dopes. Groups A, B, and C were made from different dopes of the 
same protein; all received the same 3x autoclave treatment. All MaSp1 sample groups 
were created from dopes made from the same goat-derived protein stock, but at different 
times. MaSp2 samples were made from dopes of bacterially-derived protein. Standard 


















Untreated 39.1 ± 21.2 1.8 ± 0.2 0.33 ± 0.2 6 
A 41.7 ± 3.8 1.7 ± 0.3 0.32 ± 0.08 4 
B 21.5 ± 7.1 1.6 ± 0.1 0.16 ± 0.04 2 




Not Centrifuged 73.9 ± 15.2 2.3 ± 0.3 0.82 ± 0.31 5 
Centrifuged 45.9 ± 10.2 2 ± 0.3 0.47 ± 0.14 3 
Unstretched 
MaSp2 
Untreated 189.1 ± 25 3.2 ± 0.4 3.06 ± 0.54 4 
Autoclaved 134.1 ± 29 2.5 ± 0.6 1.69 ± 0.82 4 
Stretched 
MaSp2 
Untreated 104.7 ± 32.3 57 ± 5 50.65 ± 10.55 4 
Autoclaved 79.2 ± 17.8 23 ± 11 15.24 ± 6.63 3 
 
 Unlike fibers, the mechanical properties of silk films were consistent between 




films increases the mechanical properties of spider silk films
5
. In this case, the average 
ultimate tensile stress of the films was decreased due to stretching, but the strain was 
greatly increased. It is possible that this was due to the degree of stretching used or due to 
the stretched samples being composed completely of MaSp2. Native spider dragline silk 
and many synthetic spider silk films contain at least some MaSp1, which contains 
additional strength producing crystalline motifs
3
. Although autoclaving has been shown 
to affect the structure of silkworm silk
26,27
, Hedhammer et al. showed that one round of 
autoclaving spider silk did not affect the structure of the silk
28
. It is also very likely that 
any structural changes that may have occurred due to autoclaving are “reset” when the 
protein is redoped after autoclaving. This lack of structural difference not only explains 
the similar mechanical properties of the treated and untreated films, but is also beneficial 
when comparing treated and untreated proteins, as they are more analogous to each other. 
 The resolubilization “treatment” referenced in Table 3-2 consisted of triple 
autoclaving protein powder in water, then, following autoclaving, centrifuging the 
protein-water mixture, removing the water, and freezing the pellet, or simply freezing the 
autoclaved protein-water mixture. Both samples were then lyophilized and redoped. This 
was done to determine whether it would be possible to create stocks of endotoxin-free 
protein and whether it was better to remove the water previous to freezing and subsequent 
lyophilization or not. As can be seen in Table 3-2, the films made from dopes that 
received the resolubilization treatment had mechanical properties similar to films made 
from freshly treated dopes. This indicates that it is possible to create stocks of endotoxin-
free synthetic spider silk that can be used at future times to make endotoxin-free 




stock” in a laboratory setting is that the stock will not stay endotoxin-free for very long. 
However, in certain conditions, such as a clean room, good laboratory practice, or good 
manufacturing practice, an endotoxin-free stock may be very practical and beneficial. 
Based on the “Not Centrifuged” and “Centrifuged” samples, autoclaving, freezing, and 
lyophilizing without removing the water from the dope may give better mechanical 
properties than centrifuging the dope and removing the water before freezing and 
lyophilizing. 
 Most of the samples tested in this experiment were from goat-derived spider silk 
protein. Ideally, synthetic spider silk will be produced predominately in E. coli. 
Hedhammar et al. were able to create fibers from small recombinant spider silk proteins 
produced in E. coli with low pyrogenicity by treating the bacteria with a combination of 
Tris, Ca
2+
, and EDTA before cell lysis and subsequent silk extraction
28
. While this 
method of endotoxin removal is beneficial for a bacterial production system, it is still 
difficult to produce native size spider silk proteins in bacteria. Because of this, there is 
great benefit in developing a method of endotoxin removal/destruction that can be 
applied to synthetic silk proteins regardless of the production system. In this study, a 
batch of bacterially-derived spider silk protein was treated by triple autoclaving. Results 
indicate that the treatment method also effectively removes endotoxin in the bacterially-
derived silk (Table 3-3). It is notable that autoclaving silk proteins is more easily scalable 
and likely less expensive than the endotoxin removal method developed by Hedhammar 





Table 3-3. Endotoxin levels of bacterially-derived protein and subsequent films that were 
either treated with autoclaving or untreated. Empty vials were vortexed with endotoxin-
free water in them and the water was tested. The R
2
 of the standard curve was 0.9913 for 
all tests. All samples had n=2 except B7, which had n=1 due to contaminants in the 
testing well that interfered with the absorbance reading. Silk samples below 0.25 EU/mL 












0.05 ± 0.00 






Doping + Film 
2.28 ± 0.02 
2.20 ± 0.01 








Doping + Autoclave x3 + Film 
Doping + Autoclave x3 + Film 
2.25 ± 0.01 
0.185 ± 0 
0.178 ± 0.01 
 
Conclusion 
Treating synthetic spider silk protein dopes with three consecutive autoclave cycles is 
an effective method for reducing endotoxin levels. Autoclaving at the dope stage greatly 
reduces endotoxin levels without destroying the protein-based materials or compromising 
their mechanical properties, thus yielding the best combination of endotoxin level 
reduction and mechanical properties in the final products. This combination will allow 
synthetic spider silk research to progress to meaningful biocompatibility testing and, 






Preparation of Silk Samples 
 Most samples were made from goat-derived MaSp1 recombinant spider silk 
protein. Silk proteins were extracted from goat milk and formed into either films or fibers 
using the aqueous method described previously
5,29
. Briefly, silk proteins are removed 
from defatted goat milk via tangential flow filtration, precipitation, washing, and 
subsequent lyophilization. Silk protein solutions, or dopes, are then made by mixing the 
dry protein with water and microwaving the mixture in a tightly sealed vial in 5-10 s 
bursts to achieve a minimum temperature of 120 °C under high pressure to solvate. All 
dopes used in this study were 5% (w/v) protein (150 mg protein in 3 mL water). Dopes 
were then either poured onto PDMS molds to form films or spun into fibers using a 
custom “wet spinning” spin line
5,29
. 
 Final samples were either a full film (30 mm x 6 mm x 50 µm), a six fiber bundle 
(~25 cm length, ~30 µm diameter), or just protein powder. Powder samples were 
prepared by vigorously vortexing 150 mg of protein powder in 3 mL of endotoxin-free 
water for >5 min. The mixture was then centrifuged at 4,185 x g for 10 min, after which 1 
mL of the supernatant was removed and stored for each sample. Samples were also taken 
after doping following the same procedure used for the powders. For all sample sets, 
control samples were taken prior to any treatments (including doping) and negative 
controls (endotoxin-free water) were included. 
 Some samples were made from bacterially-derived MaSp2 recombinant spider 






. The proteins were then doped and samples were prepared as 
described above. 
 As a note, the doping process is sufficient to sterilize the proteins for cell culture 
work. Because of this, the doping process was tested for its effectiveness in destroying 
endotoxin. It was shown that any reduction in endotoxin levels caused by microwaving 
was insignificant (data not included), so other treatment methods were still required. 
 
Endotoxin Removal/Destruction 
 Multiple methods of destroying endotoxins from samples were tried in this study: 
dry heat, caustic washes, water washes, and autoclaving. All equipment used for 
handling, storing, and preparing samples was depyrogenated via dry heat at 250 °C for at 
least 30 min.  
 The dry heat treatment involved heating samples to 250 °C for at least 30 min or 
180 °C for at least 3 hours. During heating, all samples were placed in a loosely covered 
glass container. After heating, samples were covered and stored in a sterile PCR hood 
until ready for use. Treated samples were only handled with endotoxin-free equipment, as 
confirmed through the use of the preferred endotoxin detection kit used in these 
experiments (data not included). 
 Caustic washes were performed with 1 M sodium hydroxide (NaOH). Treatments 
were performed on dry spider silk samples by soaking in 40 mL of NaOH for 3 min. The 
NaOH was then removed via centrifugation at 4,185 x g and the samples were rinsed with 
endotoxin-free water three to five times, which was also removed via centrifugation. 




 Autoclaving was performed on silk samples using a standard 20 min liquid cycle 
(121 °C, 15 psig, 1 min purge). The cycle was repeated three times. The door was opened 
for 1 min between each cycle to allow the autoclave pressure sensor to return to 
atmospheric pressure before proceeding. 
 Protein powder was mixed with water and then autoclaved in loosely capped 
bottles. After autoclaving, water was removed from powder samples via centrifugation at 
4,185 x g and subsequent pipetting. Dopes were made as described above then transferred 
to a clean vial that was loosely capped for autoclaving. After autoclaving, the protein 




 Some films were stretched before mechanical testing (Table 3-2). Stretching is a 
common treatment performed on synthetic spider silk fibers and films to improve their 
mechanical properties
5,29
. In this study, films were stretched in an 80:20 
isopropanol:water bath to three times their original length using a stretching apparatus 
developed by Tucker et al.
5
. Films were allowed to dry before being removed from the 




 To test whether it would be possible to make large stocks of endotoxin-free 
protein powder for future use without the silk losing its mechanical properties, two 




dope was centrifuged at 4,185 x g, the supernatant was removed, and the protein pellet 
was frozen; 2) the entire autoclaved dope was frozen. The frozen samples were then 
lyophilized, after which the protein was resolubilized in water. Films were then made 
using the standard procedure outlined above. 
 
Endotoxin Level Analyses 
 The preferred kit to determine the endotoxin levels for these experiments was the 
Pierce Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit 
(Thermo Scientific Cat# 88282), which uses UV absorbance at 405-410 nm to determine 
endotoxin concentration. This kit has a working detection range of 0.1-1.0 EU/mL. 
Endotoxin levels above 1.0 EU/mL were extrapolated using an experimentally 
determined standard curve equation. 
 Because testing a solid piece of silk material interfered with the UV absorbance 
and confounded the endotoxin level readings, 1 mL of endotoxin-free water was added to 
samples after endotoxin destruction treatments. Sample/water mixtures were vigorously 
vortexed for >5 min to break apart the silk material and remove endotoxin from the silk 
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INVESTIGATION OF THE IN VIVO BIOCOMPATIBILITY OF GOAT-DERIVED  
SPIDER SILK PROTEIN 
Chapter Preface 
 The following chapter describes in vivo biocompatibility studies in which 
materials made from goat-derived spider silk proteins were implanted into rats. Although 
native spider silk is widely accepted as biocompatible, very little biocompatibility 
research has been done on recombinant spider silk proteins and none has been reported 
on goat-derived spider silk. Because the work presented in this chapter includes the first 
in vivo studies of goat-derived spider silk, it is highly significant and impactful in the 
synthetic spider silk research field.  
 Prior to the research described in this chapter, we performed some basic in vitro 
work on goat-derived spider silk to show that multiple cell types (BHK, CHO, and PC-
12) could be grown on synthetic spider silk substrates (unpublished data), but these 
studies were merely exploratory. Because the data produced from this previous work 
have little scientific value beyond a basic assurance that cell viability is not affected when 
growing cells on silk-based materials, the studies and results are not included. 
 The work presented in this chapter shows that, in its current form, goat-derived 
spider silk is not biocompatible. A strong possibility for this unexpected negative result is 
that the proteins, which are produced in goat milk, are contaminated with casein proteins. 
Although the current protein purification method used to obtain the spider silk proteins 
includes filtration and heating to remove casein, even trace amounts could prove 




proteins tagged with histidine and purified with affinity chromatography as described in 
Chapter 2 of this dissertation will show a higher likelihood for biocompatibility. 
 It is important to note that the synthetic spider silk materials used in these studies 
were susceptible to degradation by the rats’ immune system, which likely explains much 
of the increased immunological response (e.g., increased numbers of macrophages at the 
implantation site). While this is a concern, longer term implants may be completely 
degraded and have little to no lasting effects on the host body. Although the studies 
presented here are essentially preliminary work to be followed up with longer term 
implantation studies using silk with a higher purity level, we feel that they provide a 







 Native spider silk, particularly major ampullate (dragline) silk, has long been 
known as a biocompatible material
1,2
. Dragline silk in particular has great potential in the 
biomedical field because of its biocompatibility and impressive mechanical properties
3
. 
Unfortunately, it is extremely difficult to obtain native spider silk in high quantities 
because of the difficulties associated with farming spiders due to their cannibalistic and 
territorial nature. To facilitate the use of spider silk in many different commercial 
applications, particularly biomedical applications, synthetic spider silk proteins have been 
created in multiple systems, including bacteria, silkworms, and goats
4–8
. Of these 
systems, the most consistently large quantities of silk proteins are produced in goat milk. 
 Although native spider silk and some recombinant spider silk proteins (rSSps) are 
known to be biocompatible
1,2
, no in vivo biocompatibility studies of goat-derived rSSps 
have been reported to our knowledge. In order to determine the feasibility of using goat-
derived rSSp materials for medical applications, it is essential that the silk’s 
biocompatibility be determined. Below, we describe three in vivo studies in rats aimed at 
gathering preliminary data on the biocompatibility of two goat-derived spider silk 
products: thin films and hydrogels. Rats were euthanized after 1, 2, 4, or 6 weeks and 
tissue samples were collected to determine the localized immune response of the 
implanted material. The findings from these studies establish a baseline for the current 
biocompatibility level of goat-derived rSSps and highlight areas for improving that level 





Materials and Methods 
Preparation of Implant Materials 
 Films 
Silk films were composed of goat-derived Major Ampullate Spidroin 1 (MaSp1) – 
one of the two proteins that compose dragline silk – as described previously
9
. Briefly, the 
proteins were mixed in water to create a 5% (w/v) silk solution or dope. The dope was 
then heated in 5 – 10 s bursts under pressure to at least 120 °C. The dope was treated for 
endotoxin via triple autoclaving
10
, then heated again before being poured onto 
polydimethylsiloxane (PDMS) molds that had been treated for endotoxin using dry heat 
(250 °C for 30 min). Resultant films were approximately 15 mm x 6 mm x 50 µm. 
Thin polytetrafluoroethylene (PTFE) pieces were used as controls (Grainger, 
30FZ37). The PTFE pieces were cut to match the films’ surface area as closely as 
possible (approximately 15 mm x 6 mm x 25 µm) and then treated for endotoxin by 
either dry heating at 250 °C for 30 min or triple autoclaving. Pieces treated with both 
methods were used as controls. 
 Hydrogels 
Silk hydrogels were either a 50/50 blend of MaSp1 and MaSp2, or pure MaSp1, 
depending on the study; hydrogel composition is noted for each study. Dopes were 
created and treated similarly to the dopes used to create films, but with the silk 
concentration being 20% (w/v) and the addition of 2% (v/v) propionic acid to aid 
solubility at this relatively high concentration. After autoclaving and reheating, dopes 




discs measuring 3 mm thick and 6 mm in diameter were punched out of the solidified 
dope using metal punches that had been treated for endotoxin via dry heat (250 °C for 30 
min). Hydrogels were placed in sterile petri dishes and left to soak in Dulbecco’s 
phosphate buffered saline (DPBS) for 48-72 hours prior to implantation, with the DPBS 
being replaced after 24 hours. The pH of the DPBS was tested to ensure the propionic 
acid had leeched out to avoid a potential confounding factor. 
Controls in the hydrogel study were made from Poly(ethylene Glycol) diacrylate 
(referred to herein as PEG) due to its biocompatibility and low immunological 
reponse
11,12
. 10% (w/v) PEG hydrogels were made in DPBS using PEG with an average 
MW of 10 kDa (Laysan Bio Inc, ACRL-PEG-ACRL-10K-5g). Photoinitiator (2-
Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone) (Sigma-Adlrich, 410896) was 
added to a final concentration of 0.25% (w/w), after which the mixture was vortexed 
vigorously until no particles were visible (30-60 s). Following mixing, the solution was 
exposed to UV light (365 nm) for 15 min to initiate crosslinking. PEG hydrogels were 
triple autoclaved to ensure endotoxin destruction and sterility, then allowed to sit 
overnight before being punched into implantable discs measuring approximately 3 mm 
thick and 6 mm in diameter. Discs were soaked in DPBS for 48-72 hours prior to 
implantation, with the DPBS being replaced after 24 hours. 
Animal Studies 
Wistar rats were obtained from Charles River Laboratories (Wilmington, MA). 
The rats were acclimatized for approximately 1 week prior to surgical procedures. All 
procedures were conducted in an AAALAC accredited Laboratory Animal Research 




University’s Institutional Animal Care and Use Committee. Animals were anesthetized 
with isoflurane via inhalation. The dorsa of the animals were shaved and skin was 
disinfected with chlorhexidine and 70% isopropyl alcohol. Four 1 cm incisions were 
created approximately 2 cm apart on both sides of the back (8 incisions total), 
approximately 2 cm from the midline (Figure 4-1). Subcutaneous pockets were created 
using blunt dissection and implants were placed in the pockets. Following implantation, 
incisions were closed using 3-0 polyglactin suture (Vicryl®, Ethicon J460H). 
Buprenorphine (0.1 mg/kg) (PAR Pharmaceuticals) and enrofloxacin (5 mg/kg) 
(Baytril®) were administered intramuscularly before returning rats to their home cages. 
After the allotted time post-surgery, rats were euthanized via carbon dioxide 
asphyxiation. Sutures were removed after euthanization in the case of the 1 and 2 week 
groups or 14 days post-surgery in the case of the 4 and 6 week groups. 
 
 
Figure 4-1. Graphical representation of incisions (red lines) and subcutaneous pockets 
(gray boxes) made in rats for implantation studies. Numbers indicate sample number and 





The films study was conducted on 6 rats. Films and surrounding tissue were 
harvested 4 weeks post-implantation. The rats were shaved prior to tissue collection. 
Tissue samples were fixed for ≥24 hours in formalin before being taken for 
histopathological evaluation. 
Hydrogel Study 
The hydrogel study was conducted on 18 rats. Gels and surrounding tissue were 
harvested from 6 rats at 1 week, 6 rats at 2 weeks, and 6 rats at 6 weeks. The rats were 
shaved prior to tissue collection. Tissue samples were fixed for ≥24 hours in formalin 
before being taken for histopathological evaluation. 
Histopathological Evaluation 
 Fixed tissue samples were sliced to approximately 3 mm thick, 1 cm deep, and 1.5 
cm long in preparation for embedding in paraffin. Samples were then evaluated to 
produce a semi-quantitative score of local tissue response according to ISO 10993 Part-6 
(2007)
13
, and Muhamed et al.
14
. In each histology session, the following parameters were 
studied: number of inflammatory cells (neutrophils, plasma cells, lymphocytes, and 
macrophages), number of foreign body giant cells (FBGCs), severity of necrosis, extent 
of neovascularization, extent of fibrosis, and extent of fatty infiltration. The average 
semi-quantitative score was then calculated as [(subtotal-I x 2) + subtotal-II], wherein 
subtotal-I is the sum of scores for neutrophil, lymphocyte, plasma cell, macrophage, giant 
cell, and severity of necrosis and subtotal-II is the sum of the scores for 
neovascularization, fibrosis, and fatty infiltration. The difference of the score for the test 




 A simpler, less quantitative analysis based on work by Nyska et al.
15
, in which 
results were graded from 1 to 4 based on inflammation present (lymphocytes, neutrophils, 
macrophages) and fibrous capsule size, was also done: Grade I: slight reaction with a few 
inflammatory cells; Grade II: clear inflammatory reaction with one or two giant cells; 
Grade III: fibrous tissue with inflammatory cells, lymphocytes, and giant cells; and Grade 
IV: granuloma with encapsulated implants and clear foreign-body reaction. 
Silk Clean Up 
 For one of the hydrogel implantation studies, potential contaminates were 
removed from goat-derived spider silk proteins using reverse phase chromatography 
(RPC). Proteins were solubilized in 4 M Urea at a 3% (w/v) concentration. The protein 
solutions were diluted to 2% (w/v) then run on an AKTA Avant with an XK 50 x 25 
column with 200 ml of GE SOURCE 30RPC resin (GE Healthcare, 17-5120-02). 
Proteins were eluted using acetonitrile (Sigma-Aldrich 34851-4L), 0.1% (v/v) Pierce® 
Trifluoroacetic acid (ThermoFisher Scientific 28904) at a gradient of 0 – 50% over 10 
column volumes. Fractions were collected at 45 mL intervals in 50 mL conical tubes 
(VWR 37001-468). Acetonitrile was allowed to evaporate in a chemical fume hood 
overnight before samples were concentrated by heating at 90 °C until samples had been 
reduced to 25% of their starting volume, which took approximately 12 hours. HPLC-
grade acetone (Pharmco-Aaper 32900HPLC) was then added at a 3:1 ratio 
(acetone:sample); the mixture was shaken vigorously and then stored at -20 °C overnight 
to facilitate protein precipitation. Samples were then centrifuged at 4 °C at 3200 x g for 
30 min in a Beckman Allegra
TM
 6KR centrifuge. The supernatant was analyzed via 




frozen and lyophilized. The presence of silk was verified via Western Blot analysis. This 
silk protein is designated as RPC MaSp1 throughout this manuscript. 
Western Blot 
 Western Blot analyses were conducted on RPC MaSp1 to determine which peaks 
contained silk. A 1 mL sample of each fraction was concentrated to 20 µL and diluted 1:1 
in SABU. SDS-PAGE gels were loaded with 20 µL of the concentrated fraction/SABU 
solution and run at 110 V for 80 min. Gels were transferred to a nitrocellulose membrane 
overnight at 35 mA in a wet transfer apparatus. Western Blots were performed on the 
membranes with a custom made primary antibody produced in rabbits that targets the 
native C-term of major ampullate spider silk proteins used at a 1:1000 dilution. A donkey 
anti-rabbit Alkaline Phosphatase (AP) conjugated antibody (Rockland 611-705-127) was 
used as the secondary antibody at a 1:5000 dilution. The membranes were developed in 
1-Step
TM
 NBT/BCIP Substrate Solution (ThermoFisher Scientific 34042) for imaging. 
 For the RPC MaSp1 implantation study, blood was drawn prior to surgery and 
following euthanasia. Blood was allowed to sit for >30 min before being centrifuged at 
2000 x g in a Beckman Coulter Microfuge®18 centrifuge. Serum was collected and 
aliquoted then stored at -20 °C. Serum samples were used as the primary antibody at a 
1:2000 dilution with a rabbit anti-rat IgG AP conjugated secondary antibody (Sigma-
Aldrich A6066) to determine whether the silk implanted had instigated an immune 
response, thus leading to the production of silk-specific antibodies in the rat. These 





Results and Discussion 
 The first study conducted was the film implantation study. Upon visual 
inspection, the tissue showed similar reactivity to both silk and PTFE implants. The 
histopathology results initially only included the simpler grading scale (Table 4-1). Based 
on these results, the response of spider silk films was determined to be comparable to that 
of PTFE films, providing grounds to progress to a larger scale study. One concern with 
using films again was that we could not determine the implant site of many of the 
samples. In the case of the missing rSSp films, we suspect the films had been completely 
resorbed into the body, making it difficult to find the sample implantation site when 
excising the tissue. Consequently, it was determined that hydrogels would be a better 
material to test, as they are larger and it was anticipated that they would be more stable 
long-term under in vivo conditions. 
 
Table 4-1. Average histology results from the film implantation study. Grading was on a 
whole number scale of 1 to 4: Grade I: slight reaction with a few inflammatory cells; 
Grade 2: clear inflammatory reaction with one or two giant cells; Grade 3: fibrous tissue 
with inflammatory cells, lymphocytes, and giant cells; and Grade 4: granuloma with 
encapsulated implants and clear foreign-body reaction. Standard deviations were 








Autoclaved PTFE 2 ± 0.447 4 ± 0.4 3 ± 0 10 
Dry Heated PTFE 2 ± 0.433 3 ± 0.829 3 ± 0 4 
Silk 2 ± 0.573 4 ± 0.442 3 ± 0 15 
 
 Contrary to the results we anticipated to see for the hydrogel study based on the 
results of the film study, it was very apparent when observing implant sites during 




PEG gels were highly visible and the surrounding tissue did not show any obvious signs 
of inflammation (redness, bleeding, swelling, etc.) at any time points except for 1 week. 
Any inflammation at the 1 week time point was attributed to the incision, sutures, and 
surgical procedure in general. The silk hydrogels were not readily visible due to a 
blackish-red abscess surrounding each of the implants. Although the abscess surrounding 
the silk was not as visible at 1 week as at other time points, it was present (Figure 4-2A), 
especially when compared to the PEG tissue samples (Figure 4-2B). At 6 weeks the 
encapsulation of the silk material was very apparent, while the PEG remained free of 
encapsulation (Figure 4-2C). Histopathology results confirmed the visual inspection at 
both week 1 and week 6 (Table 4-2) – inflammation and fibrosis were significantly 
higher for silk samples. Although no pictures are available of samples at week 2, 
histopathology results are presented in Table 4-2 for comparison. As can be seen, the 
week 2 results are very similar to the week 1 results. None of the rats showed any signs 







Figure 4-2. Tissue samples from rats implanted with silk and PEG hydrogels. A) Silk 
implant at 1 week. B) PEG implant at 1 week. C) PEG (top) and silk (bottom) implants at 
6 weeks. A ruler with 1 mm increments was included with each image for scale. 
 
Table 4-2. Average histopathology results for hydrogel implant study. Scores were rated 
from 1 to 4 in each category. Total score is equal to (Infl. Sub x2) + Fibro. Sub. Standard 
deviations were calculated using Microsoft Excel STDEV.P. Low n values for 6 week 
samples were due to the researchers only selecting a small sample group in light of the 
obvious encapsulation visible. 














4 ± 0 0 ± 0.484 4 ± 0 1 ± 0.492 4 ± 0 0 ± 0 
Lymphocytes 3 ± 0.2 2 ± 1 2 ± 0 1 ± 0.734 3 ± 0 0 ± 0 
Plasma Cells 1 ± 0 0 ± 0.276 1 ± 0.196 0 ± 0 1 ± 0 0 ± 0 
Macrophages 3 ± 0.2 2 ± 0.331 3 ± 0 2 ± 0.287 4 ± 0 1 ± 0 
Giant Cells 0 ± 0.498 0 ± 0.611 1 ± 0.528 0 ± 0.516 1 ± 0 0 ± 0.471 
Severity of Necrosis 4 ± 0.2 0 ± 0.276 4 ± 0 0 ± 0 4 ± 0 0 ± 0 
Infl. Sub 15 ± 0.64 5 ± 1.26 15 ± 0.632 4 ± 1.22 17 ± 0 1 ± 0.471 
Neovascularization 3 ± 0 1 ± 0.471 3 ± 0.196 2 ± 0.5 3 ± 0 0 ± 0 
Fibrosis 4 ± 0 4 ± 0.599 4 ± 0 4 ± 0 4 ± 0 4 ± 0.471 
Fatty Infiltrate 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Fibro. Sub 7 ± 0 5 ± 0.789 7 ± 0.196 6 ± 0.5 7 ± 0 4 ± 0.471 
Total score 37 ± 1.28 15 ± 2.67 37 ± 1.28 14 ± 2.68 41 ± 0 6 ± 0.471 





Following the hydrogel implantation study, more complex histology data for the 
film study samples was requested (Table 4-3). These data showed that, although the 
response due to silk and PTFE was indeed similar, the results had not actually been good. 
Because native spider silk is biocompatible, it was determined that the immune response 
was not actually due to the silk itself, but more likely due to contaminants present in the 
synthetic spider silk, such as casein, a highly immunologic milk protein. In order to 
investigate this, we sought to purify the silk using Reverse Phase Chromatography 
(RPC). 
 
Table 4-3. Average histopathology results for film implants. Scores were rated from 1 to 
4 in each category. Total score is equal to (Infl. Sub Score x2) + Fibro. Sub Score. 
Standard deviations were calculated using Microsoft Excel STDEV.P. Low n values for 
PTFE were due to tissue samples being harvested from incorrect implant locations. 
 Silk Dry Heated PTFE Autoclaved PTFE 
Polymorphonuclear Cells 1 ± 0.696 1 ± 0.471 1 ± 0.40 
Lymphocytes 2 ± 0.848 1 ± 0 1 ± 0.748 
Plasma Cells 0 ± 0.456 0 ± 0 0 ± 0 
Macrophages 2 ± 0.478 2 ± 0.373 2 ± 0 
Giant Cells 0 ± 0.322 0 ± 0 0 ± 0 
Severity of Necrosis 1 ± 0.832 0 ± 0 0 ± 0.4 
Infl. Sub Score 7 ± 3.047 4 ± 0.687 4 ± 0.748 
Neovascularization 2 ± 0.730 1 ± 0.943 1 ± 0.4 
Fibrosis 4 ± 0 4 ± 0.373 4 ± 0 
Fatty Infiltrate 0 ± 0 0 ± 0 0 ± 0 
Fibro. Sub Score 6 ± 0.730 5 ± 1.067 5 ± 0.4 
Total score 20 ± 6.608 14 ± 1.893 14 ± 1.744 
n 17 6 5 
 
 Spider silk dopes containing 2% spider silk in 4 M Urea were submitted to RPC 
as described in Materials and Methods. Peaks containing spider silk (as shown by 
Western Blot analysis) eluted in acetonitrile were collected. After acetone precipitation, 




doped in nanopure water and treated for endotoxins via triple autoclaving. The protein 
was then redoped and hydrogels were made from it under sterile conditions. The RPC 
MaSp1 hydrogels, which were noticeably softer than non-RPC MaSp1 hydrogels, were 
implanted into 2 rats. A third rat was implanted with non-RPC MaSp1 as a positive 
control. PEG was again used as the negative control.  
 Two weeks post-implantation necropsies were performed on all 3 rats. After just 2 
weeks, many of the RPC MaSp1 gels had been resorbed, either partially or completely. 
This was likely due to the decreased stiffness of the RPC MaSp1 gels, which made it 
much easier for the gels to be broken into very small pieces via mechanical forces, such 
as handling with forceps or pressure on the implantation site post-surgery. These small 
gel pieces were more accessible to the macrophages, making them easier to digest. A 
capsule was still visible around remaining silk implants, although it was less pronounced 
than those in the original hydrogel study and (visibly) the RPC MaSp1 implants were less 
encapsulated than the non-RPC MaSp1 hydrogels. Visual inspection (Figure 4-3) and 
histopathology results (Table 4-4) indicated that the inflammatory response was similar 





Figure 4-3. Tissue samples from rats implanted with silk and PEG hydrogels. Samples 
were collected 2 weeks post-implantation. A) RPC MaSp1 hydrogel; the gel is hard to see 
because it was broken in pieces during implantation – arrows have been added to indicate 
the 3 largest pieces of the gel. B) Silk hydrogel implant. C) PEG hydrogel implant. A 
ruler with 1 mm increments was included with each image for scale. 
 
Table 4-4. Average histopathology results for hydrogel implant study. Scores were rated 
from 1 to 4 in each category. Total score = (Infl. Sub Score x2) + Fibro. Sub Score. 
Standard deviations were calculated using Microsoft Excel STDEV.P. 
 RPC MaSp1 Silk PEG 
Polymorphonuclear Cells 1 ± 0.661 3 ± 0 1 ± 0.64 
Lymphocytes 2 ± 0.331 2 ± 0 1 ± 0.64 
Plasma Cells 0 ± 0.331 0 ± 0 0 ± 0 
Macrophages 4 ± 0 3 ± 0 2 ± 0 
Giant Cells 3 ± 0.696 1 ± 0 0 ± 0.64 
Severity of Necrosis 0 ± 0.484 3 ± 0 0 ± 0.276 
Infl. Sub Score 10 ± 1.479 12 ± 0 5 ± 1.323 
Neovascularization 2 ± 0.331 3 ± 0 1 ± 0.493 
Fibrosis 2 ± 1.936 4 ± 0 4 ± 0 
Fatty Infiltrate 0 ± 0 0 ± 0 0 ± 0 
Fibro. Sub Score 3 ± 2.058 7 ± 0 5 ± 0.493 
Total score 23 ± 4.885 31 ± 0 14 ± 2.9 
n 8 4 12 
 
 To determine whether the rats in the RPC MaSp1 study were creating antibodies 
to the spider silk, plasma was taken from the rats for use as a primary antibody against 
MaSp1 silk in a Western Blot analysis, with an anti-rat IgG secondary antibody. The 




response to the silk implant, implying that the silk hydrogel had elicited an immune 
response in the rats. 
 
Figure 4-4. Western Blot analysis of rSSp using rat blood as the primary antibody. Left: 
blood drawn prior to implantation (pre-surgery). Right: blood drawn during necropsies (2 
weeks post-surgery). Black arrow indicates 64 kDa where the MaSp1 band is present on 
the right, but missing on the left. The molecular weight standard was the Bio-Rad Dual 
Color Precision Plus Protein
TM
 Standard.  
 
 Because of the genetic similarity between synthetic spider silk and native spider 
silk, it is more likely a contaminate present, possibly acting as an adjuvant, in the goat-
derived transgenic spider silk proteins that is causing an immune response than the silk 
itself. Further clean-up of the silk and the material production conditions should lead to a 
decreased immune response. It is also likely that the immune response seen in the RPC 
MaSp1 hydrogel study was due to the rats’ bodies responding as they would to nearly any 
foreign material: breaking it down to remove it from their system. We suspect that a 




the case, an early immune response is not only expected, but could actually be beneficial, 
as it would facilitate removal of the silk protein structure over time, which would be ideal 
for applications such as cell scaffolds and drug delivery. 
Conclusion 
 At their current stage, goat-derived synthetic spider silk proteins are not 
sufficiently biocompatible due to contaminants in the proteins. Given the nature of the 
farm environment the proteins come from and, more significantly, the environment the 
proteins are purified in, as well as the purification process itself, these results are not all 
together unexpected. To further elucidate whether synthetic spider silk can be used as an 
effective biomaterial, more extensive work will need to be done. Further research into 
purifying and cleaning the silk proteins through RPC and other methods is still needed. It 
is highly possible that, over longer periods of time, the silk (especially the RPC MaSp1) 
will be completely degraded by the host, unlike the PTFE and PEG controls used in these 
experiments. This biodegradability would partially negate many of the concerns relating 
to the immediate inflammatory response the silk creates, especially because the response 
is localized, not systemic. Regardless, further work to investigate potential contaminates 
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 One of the key concepts in biological engineering is to harness the power of 
existing biological systems to develop innovative systems that either mimic or improve 
on naturally occurring ones, particularly with the goal of creating marketable products 
and/or improving human lives. A core principle in any field of engineering that readily 
applies to biological engineering is to design, build, and test. Both of these concepts were 
employed during the work described in this dissertation. As was discussed throughout, 
spider silk proteins have great potential for use in producing marketable materials, 
particularly biomaterials for medical applications, but the current quantities and purity 
level of spider silk are not sufficient for these to come to fruition. 
 In producing a new goat cell line to be used to create improved “spider goats,” 
multiple iterations of designing, building, and testing were necessary. It was initially 
proposed to use targeted gene editing to replace a native goat milk protein gene with a 
spider silk protein gene such that it would be produced using the goat’s native regulatory 
controls. Multiple gene editing systems were designed to target regions of the goat 
genome, but upon building and testing these systems, it was ultimately decided that, 
while it may be possible to incorporate silk in this way, the time, resources, and potential 
for failure (if the gene knockout proved fatal or the goats were unable to produce any 
milk), would likely not be compensated by the theoretical improvement of the silk 
proteins quality and quantity. Consequently, an effective and practical random integration 
method was designed and tested to facilitate the creation of new goats. As described in 




goats to produce silk proteins that can be purified more efficiently and more completely. 
This will allow for an overall increase in protein yield and purity, thus enabling research 
on spider silk as a biomaterial to move forward more effectively. 
 Although current recombinant spider silk proteins are being used to produce and 
evaluate a variety of materials, their biocompatibility had not been tested. Also, there was 
no established method for dealing with the issue of endotoxin contamination in the 
proteins that was likely to occur, especially in the bacterially-derived proteins. Lack of 
biocompatibility information and an endotoxin removal procedure were two major 
roadblocks to using these silk-based biomaterials for medical applications. In determining 
the best protocol for decreasing the endotoxins present in goat-derived silk to an FDA 
acceptable level, multiple methods were evaluated for their effectiveness as well as their 
impact on the mechanical properties of the silk materials. After building, testing, and 
redesigning protocols based on general techniques for endotoxin removal, a method was 
established to destroy endotoxins in spider silk proteins (regardless of the production 
source – goats or bacteria) without compromising the mechanical properties of the silk-
based materials made from those proteins.  
Following the endotoxin preparatory work, the biocompatibility tests described in 
Chapter 4 could be developed. The procedure for these tests was redesigned multiple 
times to determine the best materials to use to efficiently test the silk proteins. Initially, 
thin films were used, but it was determined that hydrogels would be a better testing 
material, as the films degraded quickly, making it difficult to find the implantation site. 
The control materials also had to be evaluated following initial studies to find a better 




feedback that could be used to redesign the silk purification process in an attempt to 
decrease the inflammatory response caused by silk-based materials. The results of these 
tests also re-emphasize the importance of creating new goats to produce proteins that can 
be purified more completely, as mentioned above. Through these in vivo studies, we have 
established a baseline for the biocompatibility of goat-derived silk proteins. This baseline 
gives us essential information regarding the future work needed to improve our 
recombinant silk protein purification process. For this future work, we suggest that 
characterization of the impurities present in our silk protein be completed to elucidate 
areas of improvement for the silk purification process. We have also established a 
standardized protocol for effectively testing silk-based materials regardless of its source 







SUMMARY AND CONCLUSIONS 
 Recombinant spider silk proteins (rSSps) produced in transgenic hosts, 
particularly goats, hold great promise for use in the biomedical field. Increasing the 
amount and purity of these rSSps are two critical achievements needed to move protein-
based materials from laboratory studies to clinic applications. The new “spider goat” cell 
line described in Chapter 2 will allow for production of more goat-derived proteins that 
can be purified more completely. Even with this improvement, endotoxin contamination 
is still a concern for these proteins as well as proteins acquired from other sources. The 
method established to remove endotoxins in rSSps described in Chapter 3, significantly 
increases the likelihood of creating medical-grade proteins.  
Although the biocompatibility tests described in Chapter 4 did not yield the 
positive results we anticipated, the data obtained are valuable in that they have 
established a biocompatibility baseline for goat-derived rSSps. This baseline creates a 
starting point for future biocompatibility work – characterizing the contaminants present 
in the spider silk proteins and then determining the best method for removing those 
contaminants. This could be accomplished through the use of mass spectrometry, which 
could verify whether the immunological protein casein is present in our protein mixtures 
and provide information about whether or not other non-silk proteins are present.  
More important than the biocompatibility baseline established through this work 
is the establishment of a standardized method for testing the biocompatibility of rSSps 
(whether from goats or another source). By having a standardized protocol, future studies 




that could require the unnecessary use of more animal lives than needed. Although 
further work will be needed to improve the purity level of rSSps, the work completed for 
this dissertation has helped to establish a roadmap for that future work, moving goat-





















CHAPTER 3 SUPPLEMENTARY INFORMATION 
 
Table A1-1. Endotoxin levels of goat-derived synthetic spider silk protein treated with 
various endotoxin destruction techniques. Although all protein came from the same stock, 
horizontal lines are used to separate different sample batches that were treated and tested 
at different times. The R
2
 of the standard curve was ≥ 0.989 for all experiments. Silk 
samples below 0.25 EU/mL are in bold. Sample 9 had n=2 due to a negative absorbance 
on one of the sample replicates that was excluded from the average. Sample 15 was made 
on untreated PDMS. Standard deviations were calculated using STDEV.P in Microsoft 
Excel. 











NaOH rinse + H20 rinse 
NaOH rinse + H20 rinse 
5.02 ± 0.07 
2.08 ± 0.11 











Doping + Autoclave x3 
Doping + Autoclave x3 + Film 
5.20 ± 0.24 
0.307 ± 0.10 











Doping + Autoclave x3 
Doping + Autoclave x3 + Film 
1.73 ± 0.10 
0.063 ± 0.01 











Doping + Autoclave x3 
Doping + Autoclave x3 + Film 
1.99 ± 0.05 
0.115 ± 0.00 











Doping + Autoclave x3 
Doping + Autoclave x3 + Film 
1.79 ± 0.13 
0.098 ± 0.01 














Doping + Film 
Doping + Film 
2.23 ± 0.02 
1.17 ± 0.02 













Doping + Autoclave x3 
Doping + Autoclave x3 + Film 
Doping + Autoclave x3 + Film 
2.28 ± 0.01 
0.136 ± 0.01 
0.202 ± 0.02 
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